STOCK TITAN

[Form 4] Inspire Medical Systems, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Inspire Medical Systems (INSP) director Gary L. Ellis reported acquiring 372 shares of common stock on October 14, 2025. The shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reported price of $78.84 per share.

Following this transaction, Ellis beneficially owns 6,454 shares, held directly. This filing reflects routine director compensation settled in stock rather than cash.

Inspire Medical Systems (INSP) il direttore Gary L. Ellis ha riferito di aver acquistato 372 azioni di azioni ordinarie in data 14 ottobre 2025. Le azioni sono state ricevute in sostituzione di onorari in contanti secondo la politica di compensazione per i membri del Consiglio non dipendenti della società, ad un prezzo riportato di $78,84 per azione.

A seguito di questa operazione, Ellis detiene beneficiariamente 6.454 azioni, conservate direttamente. Questa comunicazione riflette una compensazione routinaria del direttore liquidata in azioni anziché in contanti.

Inspire Medical Systems (INSP) el director Gary L. Ellis informó sobre la adquisición de 372 acciones de acciones comunes en 14 de octubre de 2025. Las acciones fueron recibidas en lugar de honorarios en efectivo conforme a la Política de Compensación para Directores No Empleados de la empresa, a un precio reportado de $78.84 por acción.

Después de esta operación, Ellis posee beneficiosamente 6.454 acciones, mantenidas directamente. Este archivo refleja la compensación rutinaria del director liquidada en acciones en lugar de efectivo.

Inspire Medical Systems (INSP)의 이사 Gary L. Ellis가 2025년 10월 14일372주의 보통주를 취득했다고 보고했습니다. 주식은 회사의 비피고용 이사 보수 정책에 따라 현금 수수료 대신 수령되었으며, 주당 보고 가격은 $78.84였습니다.

이 거래 이후 Ellis는 실질적으로 6,454주를 보유하고 있으며, 이는 직접 보유입니다. 이 공시서는 현금이 아닌 주식으로 settlement된 이사 보수를 나타낸 일상적인 거래를 반영합니다.

Inspire Medical Systems (INSP) le directeur Gary L. Ellis a annoncé l'acquisition de 372 actions ordinaires le 14 octobre 2025. Les actions ont été obtenues en remplacement de frais en espèces au titre de la Politique de rémunération des administrateurs non salariés de l'entreprise, à un prix déclaré de $78,84 par action.

À la suite de cette transaction, Ellis possède bénéficiairement 6 454 actions, détenues directement. Cette notice reflète une compensation habituelle des administrateurs réglée en actions plutôt qu'en espèces.

Inspire Medical Systems (INSP) Direktor Gary L. Ellis meldete den Erwerb von 372 Aktien Stammaktien am 14. Oktober 2025. Die Aktien wurden anstatt Bargeldgebühren gemäß der Richtlinie des Unternehmens zur Vergütung von Direktoren ohne Beschäftigungsverhältnis empfangen, zu einem gemeldeten Preis von $78,84 pro Aktie.

Im Anschluss an diese Transaktion besitzt Ellis wirtschaftlich gesehen 6.454 Aktien, direkt gehalten. Diese Offenlegung spiegelt eine routinemäßige Direktorvergütung wider, die in Aktien statt in Bargeld abgewickelt wird.

Inspire Medical Systems (INSP) مديرها Gary L. Ellis ذكر أنه اشترى 372 سهماً عاديّاً في 14 أكتوبر 2025. تم استلام الأسهم بدلاً من أتعاب نقدية وفقاً لسياسة تعويض أعضاء مجلس الإدارة غير العاملين في الشركة، بسعر مُبلغ عنه قدره $78.84 للسهم.

بعد هذه المعاملة، يمتلك Ellis ملكِية فعّالة 6,454 سهماً، وهو مالكها مباشرةً. هذه الإبلاغ يعكس تعويضاً عاديّاً للمخرجين يُسوّى بالأسهم بدلاً من النقد.

Inspire Medical Systems (INSP) 董事 Gary L. Ellis 报告在 2025年10月14日 收购了 372股普通股。根据公司“非雇员董事薪酬政策”,这些股票是以 $78.84 美元/股的价格 以股票代替现金费用 的形式取得。

此次交易后,Ellis 实际持有6,454股,为直接持有。这份申报文件反映了以股票而非现金结算的常规董事薪酬。

Positive
  • None.
Negative
  • None.

Inspire Medical Systems (INSP) il direttore Gary L. Ellis ha riferito di aver acquistato 372 azioni di azioni ordinarie in data 14 ottobre 2025. Le azioni sono state ricevute in sostituzione di onorari in contanti secondo la politica di compensazione per i membri del Consiglio non dipendenti della società, ad un prezzo riportato di $78,84 per azione.

A seguito di questa operazione, Ellis detiene beneficiariamente 6.454 azioni, conservate direttamente. Questa comunicazione riflette una compensazione routinaria del direttore liquidata in azioni anziché in contanti.

Inspire Medical Systems (INSP) el director Gary L. Ellis informó sobre la adquisición de 372 acciones de acciones comunes en 14 de octubre de 2025. Las acciones fueron recibidas en lugar de honorarios en efectivo conforme a la Política de Compensación para Directores No Empleados de la empresa, a un precio reportado de $78.84 por acción.

Después de esta operación, Ellis posee beneficiosamente 6.454 acciones, mantenidas directamente. Este archivo refleja la compensación rutinaria del director liquidada en acciones en lugar de efectivo.

Inspire Medical Systems (INSP)의 이사 Gary L. Ellis가 2025년 10월 14일372주의 보통주를 취득했다고 보고했습니다. 주식은 회사의 비피고용 이사 보수 정책에 따라 현금 수수료 대신 수령되었으며, 주당 보고 가격은 $78.84였습니다.

이 거래 이후 Ellis는 실질적으로 6,454주를 보유하고 있으며, 이는 직접 보유입니다. 이 공시서는 현금이 아닌 주식으로 settlement된 이사 보수를 나타낸 일상적인 거래를 반영합니다.

Inspire Medical Systems (INSP) le directeur Gary L. Ellis a annoncé l'acquisition de 372 actions ordinaires le 14 octobre 2025. Les actions ont été obtenues en remplacement de frais en espèces au titre de la Politique de rémunération des administrateurs non salariés de l'entreprise, à un prix déclaré de $78,84 par action.

À la suite de cette transaction, Ellis possède bénéficiairement 6 454 actions, détenues directement. Cette notice reflète une compensation habituelle des administrateurs réglée en actions plutôt qu'en espèces.

Inspire Medical Systems (INSP) Direktor Gary L. Ellis meldete den Erwerb von 372 Aktien Stammaktien am 14. Oktober 2025. Die Aktien wurden anstatt Bargeldgebühren gemäß der Richtlinie des Unternehmens zur Vergütung von Direktoren ohne Beschäftigungsverhältnis empfangen, zu einem gemeldeten Preis von $78,84 pro Aktie.

Im Anschluss an diese Transaktion besitzt Ellis wirtschaftlich gesehen 6.454 Aktien, direkt gehalten. Diese Offenlegung spiegelt eine routinemäßige Direktorvergütung wider, die in Aktien statt in Bargeld abgewickelt wird.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ellis Gary Lee

(Last) (First) (Middle)
C/O INSPIRE MEDICAL SYSTEMS, INC.
5500 WAYZATA BLVD., SUITE 1600

(Street)
GOLDEN VALLEY MN 55416

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/14/2025 A 372(1) A $78.84 6,454 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.
/s/ Bryan Phillips, Attorney-in-Fact for Gary L. Ellis 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did INSP director Gary L. Ellis report on Form 4?

He reported acquiring 372 shares of Inspire Medical Systems common stock on October 14, 2025.

Why were the INSP shares issued to Gary L. Ellis?

They were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.

What was the reported price for the INSP shares?

The filing lists a price of $78.84 per share.

How many INSP shares does Ellis own after the transaction?

He beneficially owns 6,454 shares following the reported transaction.

Is the ownership direct or indirect?

The filing indicates Direct (D) ownership.

What was the security involved in the INSP Form 4?

The transaction involved Common Stock of Inspire Medical Systems, Inc.
Inspire Medical

NYSE:INSP

INSP Rankings

INSP Latest News

INSP Latest SEC Filings

INSP Stock Data

2.29B
26.85M
1.14%
117.62%
7.94%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
GOLDEN VALLEY